PHATHOM PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 12-month period ending 2023-12-31, per its 10-K/A filed 2024-06-14.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2024-06-14
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2023-03-31 was 0.00%.
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2022-03-31 was 0.00%.
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2021-03-31 was 0.00%.
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2020-03-31 was 0.00%.
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2021 was 0.00%.
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2020 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|
| 2023-12-31 | 0.00% 10-K/A · filed 2024-06-14 | |||
| 2023-09-30 | 0.00% 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | 0.00% 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | 0.00% 10-Q · filed 2023-05-10 | |||
| 2022-12-31 | 0.00% 10-K/A · filed 2024-06-14 | |||
| 2022-09-30 | 0.00% 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | 0.00% 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | 0.00% 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | 0.00% 10-K · filed 2023-02-28 | |||
| 2021-09-30 | 0.00% 10-Q/A · filed 2022-11-09 | |||
| 2021-06-30 | 0.00% 10-Q · filed 2022-08-02 | |||
| 2021-03-31 | 0.00% 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | 0.00% 10-K · filed 2021-03-30 | |||
| 2020-09-30 | 0.00% 10-Q · filed 2020-11-10 | |||
| 2020-06-30 | 0.00% 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | 0.00% 10-Q · filed 2020-05-12 | |||
| 2019-12-31 | 0.00% 10-K · filed 2020-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |